C12Q 2600/106
Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
C12Q2600/106 (Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism) appears on 3,609 US grants and 9,092 published applications in this corpus.
Search patents in C12Q- Granted patents
- 3,609
- Published applications
- 9,092
- Assignees
- 2,650
- Inventors
- 14,830
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 2 | 0 |
| 1996 | 5 | 0 |
| 1997 | 12 | 0 |
| 1998 | 11 | 0 |
| 1999 | 15 | 0 |
| 2000 | 13 | 0 |
| 2001 | 21 | 5 |
| 2002 | 19 | 49 |
| 2003 | 15 | 76 |
| 2004 | 20 | 92 |
| 2005 | 13 | 153 |
| 2006 | 26 | 205 |
| 2007 | 24 | 219 |
| 2008 | 41 | 235 |
| 2009 | 75 | 353 |
| 2010 | 105 | 417 |
| 2011 | 125 | 397 |
| 2012 | 123 | 389 |
| 2013 | 129 | 375 |
| 2014 | 146 | 368 |
| 2015 | 168 | 491 |
| 2016 | 150 | 606 |
| 2017 | 189 | 521 |
| 2018 | 245 | 496 |
| 2019 | 270 | 567 |
| 2020 | 289 | 490 |
| 2021 | 302 | 498 |
| 2022 | 269 | 507 |
| 2023 | 225 | 488 |
| 2024 | 216 | 455 |
| 2025 | 197 | 353 |
| 2026 | 139 | 287 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Biomarkers of renal osteodystrophy type6 Oct 2026US 12,753,440 B2The Trustees of Columbia University in the City of New York
- Methods relating to anti-IL-1 therapy and anti-IL-6 therapy and hypersensitivity6 Oct 2026US 12,753,443 B2The Board of Trustees of the Leland Stanford Junior University
- Use of simultaneous marker detection for assessing diffuse glioma and responsiveness to treatment6 Oct 2026US 12,753,446 B2BioVentures, LLC
- Method of predicting therapeutic response and prognosis of metastatic breast cancer to chemotherapeutic agents, and treating metastatic breast cancer6 Oct 2026US 12,753,447 B2Samsung Life Public Welfare Foundation
- Molecular profiling of tumors6 Oct 2026US 12,754,193 B2Caris MPI, Inc.
- Methods for cancer detection and monitoring8 Oct 2026US 2026/0308683 A1Natera, Inc.
- Genomic alterations in the tumor and circulation of pancreatic cancer patients8 Oct 2026US 2026/0308686 A1The Johns Hopkins University
- Biomarker for prediction of immunotherapy outcomes and precision treatment strategies and uses thereof8 Oct 2026US 2026/0308688 A1Ohio State Innovation Foundation
- Novel use of an inhibitor of the poly-adp ribose polymerase (parp) in the treatment of cancer8 Oct 2026US 2026/0308691 A1Tesaro, Inc.
- Dlk1-targeting antibodies and uses thereof1 Oct 2026US 2026/0297185 A1
Most cited
By later US patents
- Determination of status in neoplastic disease237US 4,968,603 AThe Regents of the University of California · 1990
- Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same231US 6,309,823 B1Affymetrix, Inc. · 2001
- Analysis of genetic polymorphisms and gene copy number217US 6,468,744 B1Affymetrix, Inc. · 2002
- Detection of copy number changes in colon cancer192US 6,326,148 B1The Regents of the University of California · 2001
- Methods of assigning treatment to breast cancer patients186US 7,171,311 B2Rosetta Inpharmatics LLC · 2007